AbbVie Acquires Apogee Therapeutics for $10.9 Billion

AbbVie (NYSE:ABBV) announced it has agreed to acquire Apogee Therapeutics in an all-cash deal valued at US$10.9 billion. The transaction focuses on expanding AbbVie's immunology and respiratory disease pipeline with several clinical-stage candidates. The deal is described as AbbVie's largest acquisition in more than five years and includes a premium to Apogee's recent trading levels.

Deal Details

• Total Value: $10.9 billion in cash.
• Target: Apogee Therapeutics.
• Payment Method: All cash.
• Premium: Includes a premium to Apogee's recent trading price.
• Expected Close: Not yet announced.

Rationale for the Deal

AbbVie aims to strengthen its pipeline in immunology and respiratory diseases, two key areas for the company. The acquisition adds several late-stage clinical candidates, helping to offset declining Humira revenue due to biosimilar competition.

Regulatory Challenges

The deal is subject to regulatory review in the U.S. and possibly other jurisdictions. AbbVie has not disclosed any anticipated regulatory hurdles, but large pharma deals often face antitrust scrutiny.

Impact on Stocks

The source did not provide details on stock reactions. Typically, large acquisitions can lead to stock price movements. Investors watch for potential EPS dilution or accretion over the long term.